Progeria: what it is, causes, symptoms and treatment

The word progeria comes from Greek roots meaning "prematurely old". In Hutchinson-Gilford progeria syndrome, children appear to age many times faster than usual. MedlinePlus Genetics describes a condition in which the dramatic, rapid appearance of ageing begins in childhood, with children typically looking normal at birth and in early infancy.

The condition was first described in the late 19th century. A research review notes that it was reported by Jonathan Hutchinson and Hastings Gilford, and that the genetic cause was only found in 2003. It remains one of the rarest genetic conditions known, so most GPs and many paediatricians will never meet a case.

Several other rare conditions can look similar, so a specialist genetics service is usually involved in confirming a diagnosis. This page deals only with classic Hutchinson-Gilford progeria.

There is currently no cure. The most important advance is lonafarnib, a farnesyltransferase inhibitor originally developed for cancer that reduces the harmful effects of progerin. In a first trial of 25 children aged 3 to 16 years, a research review reports improved vascular stiffness (a median 35% fall in pulse wave velocity in 18 children), better bone density in most, and improved hearing, although weight gain results were mixed.

The NHS Medicines Awareness Service notes the US approval of lonafarnib for children over 1 year, based on two single-arm trials of 62 patients that reported a 60% reduction in mortality and 2.5 years greater average survival than matched untreated patients. Whether and how the medicine is available in the UK is a question for the specialist team.

Other approaches, including combinations of existing drugs and genome editing, remain at research stage. The review describes CRISPR-based correction as a future possibility still to be evaluated, so families should be cautious about claims of imminent cures.

MedlinePlus says affected children grow more slowly than other children and do not gain weight at the expected rate. A characteristic facial appearance develops, with prominent eyes, a thin nose with a beaked tip, thin lips, a small chin and protruding ears. Features usually appear in the first couple of years.

• Slow growth and slow weight gain (faltering weight).

• Hair loss, including scalp hair, and thin, aged-looking skin.

• Loss of fat under the skin, so veins may show more clearly.

• Joint abnormalities and stiffness.

• Reduced bone density; the research review lists osteoporosis alongside growth impairment and heart disease.

• Progressive hardening of the arteries, which is the most serious feature.

Progeria is caused by changes in the LMNA gene. This gene provides the instructions for lamin A, a protein that helps hold the nucleus of a cell in shape. In HGPS, a single small change in the gene leads to an abnormal, shortened lamin A protein called progerin, which cannot be processed properly.

A research review explains that progerin stays permanently attached to the inner membrane of the nucleus and damages the cell. Cells in progeria show unstable nuclear structure, impaired DNA repair and early senescence, which means they stop dividing and die sooner. The review adds that small amounts of progerin are also produced during normal ageing, which is why progeria is of wider scientific interest.

MedlinePlus Genetics classes progeria as an autosomal dominant condition, but says it results from new gene changes and almost always occurs in families with no history of it. In practical terms, parents of an affected child do not usually carry the change, although genetic counselling can address this directly.

Diagnosis begins with recognition of the pattern: slow growth, hair loss, characteristic features and loss of fat under the skin, in a child who was well at birth. A genetic test of the LMNA gene then confirms it. This page does not cover the UK testing pathway in detail, so a paediatrician or clinical genetics service is the right place to ask.

Because intellectual development is not affected, MedlinePlus notes, children usually take part fully in learning and social life, and many parents describe being struck by the contrast between a child's outlook and the physical challenges they face.

Arterial disease is what limits life expectancy. MedlinePlus says the severe hardening of the arteries begins in childhood and greatly increases the chance of heart attack or stroke at a young age, with complications that can worsen over time and are life-threatening.

A research review states that death occurs at a mean age of about 14.6 years, usually due to cardiovascular complications. This is an average from earlier studies, and outcomes vary. Newer treatments may improve on it, and families should ask a specialist team what the most current evidence suggests.

Care is usually led by a specialist team, with regular monitoring of the heart and arteries and attention to growth and bones. The published sources used here focus on the science rather than day-to-day care, so families should ask their team for practical advice on school, physical activity, pain and psychological support.

Because children are intellectually unaffected, many take part in school and friendships, and support for siblings and parents matters as much as medical care.

Because the arteries are affected, the NHS stroke guidance applies. It says the main symptoms of a stroke can happen suddenly: one side of the face may droop, one arm may be weak or numb so that it cannot be lifted, and speech may be slurred or confused. It says to call 999 straight away, even if the symptoms have stopped, and not to drive yourself to A&E.

The NHS heart attack guidance says to call 999 for chest pain that feels tight or like squeezing, pain spreading to the arms, neck or jaw, severe difficulty breathing, or someone who has passed out and is not responding normally. For any other new symptom, contact the child's specialist team or NHS 111 for advice.

No dedicated UK patient information page on progeria was found for this guide, so the sources are international or research-based and are marked as such. In the UK, the usual route to diagnosis and care is through a paediatrician and a clinical genetics service, with cardiology and other specialists involved as needed.

Because the condition is so rare, families may be referred to a specialist centre. Ask your team about how the medicine lonafarnib can be accessed in the UK, what monitoring is planned for the heart and arteries and whether there are research studies you could join. Private opinions are possible but rare conditions are usually best managed through NHS specialist networks.